Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Intelligent Commercializationâ„¢ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

From activity to impact: 5 takeaways from MAPS Americas 2026

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercializationâ„¢. Now we’re back in the…